MedTrace Logo

Exploring the Influence of Elevated CO2 on Allergic Skin

NCT06244524 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-02-06

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the impact of elevated indoor CO2 levels on skin barrier function and inflammation in healthy adults. The main questions it aims to answer are:

How do increased indoor CO2 levels contribute to type 2 inflammation and barrier dysfunction in human skin? What is the demonstrable impact of high CO2 exposure on the human skin barrier and transcriptome? Participants will be exposed to controlled levels of CO2 in either well-ventilated or non-ventilated (closed) bedrooms.

We will evaluate epithelial barrier function by electrical impedance spectroscopy (EIS), collect skin biopsy samples, and investigate the change induced by high indoor CO2 exposure. Healthy adults meeting the inclusion criteria will be included and those with chronic skin conditions, allergies, or recent systemic therapy will be excluded.

Researchers will compare participants exposed to elevated CO2 levels in closed bedrooms with those in well-ventilated bedrooms to determine if skin barrier integrity and transcriptome variations are observed.

Conditions

  • Affects of Elevated Indoor CO2

Interventions

OTHER

High indoor CO2 exposure

The participants will stay and sleep for eight hours in a closed bedroom.

Sponsors & Collaborators

  • Swiss Institute of Allergy and Asthma Research

    lead OTHER

Principal Investigators

  • Yasutaka Mitamura, MD PhD · Swiss Institute of Allergy and Asthma Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-31
Primary Completion
2024-09-30
Completion
2025-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06244524 on ClinicalTrials.gov